• Publications
  • Influence
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
TLDR
Notably, major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment, and while the recent increase in treatment is encouraging, inadequate treatment is a serious concern.
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
TLDR
The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.
The Inventory of Depressive Symptomatology (IDS): psychometric properties.
TLDR
Analysis of sensitivity to change in symptom severity in an open-label trial of fluoxetine showed that the IDs-C and IDS-SR were highly related to the 17-item Hamilton Rating Scale for Depression.
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
TLDR
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
TLDR
When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.
Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.
TLDR
It is concluded that research on depressive illness would be well served by greater consistency in the definition change points in the course of illness, and proposes an internally consistent, empirically defined conceptual scheme for the terms remission, recovery, relapse, and recurrence.
The inventory for depressive symptomatology (IDS): Preliminary findings
TLDR
The Inventory for Depressive Symptomatology appears applicable to both inpatients and outpatients with endogenous, atypical, and nonendogenous major depression, and may have utility with dysthymics.
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report
TLDR
The QIDS-SR16 andQIDS-C16, as well as the longer 30-item versions, have highly acceptable psychometric properties and are treatment sensitive measures of symptom severity in depression.
Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder.
TLDR
Comorbid lifetime and current axis I disorders in 288 patients with bipolar disorder and the relationships of these comorbid disorders to selected demographic and historical illness variables showed associations with earlier age at onset of affective symptoms and syndromal bipolar disorder.
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
TLDR
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.
...
1
2
3
4
5
...